JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

The Journal of Nuclear Medicine Vol. 35 No. 1 57-62
© 1994 by Society of Nuclear Medicine
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nocaudie-Calzada, M.
Right arrow Articles by Marchandise, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nocaudie-Calzada, M.
Right arrow Articles by Marchandise, X.

Iodine-123-Tyr-3-Octreotide Uptake in Pancreatic Endocrine Tumors and in Carcinoids in Relation to Hormonal Inhibition by Octreotide

Marie Nocaudie-Calzada, Damien Huglo, Marc Deveaux, Bruno Carnaille, Charles Proye and Xavier Marchandise

Department of Nuclear Medicine and Adult Surgical Professorial Unit, General and Endocrine Surgery, Hôpital Huriez, CHU de Lille, Lille, France

Correspondence: For correspondence and reprints contact: Dr. Marie Nocaudie-Calzada, Dept. of Nuclear Medicine, Hôpital Huriez, CHU de Lille, 59037 Lille Cedex, France.

ABSTRACT

Uptake of 123I-Tyr-3-octreotide (TOCT) by hormone-secreting abdominal tumors was studied to compare scintigraphic observations with the reduction in hormone levels brought about by a brief therapeutic test. Methods: A prospective study was conducted on 17 patients, totalizing 46 proven lesions, with endocrine tumors of the pancreas (10 patients, 20 lesions) and/or carcinoid metastases (8 patients, 26 lesions). Tumor hormonal hypersecretion was inhibited by octreotide. Results: There was good agreement between the results of these examinations. Conclusions: The detection of abdominal tumors using this radiotracer is strongly related to its functional characteristics. Variations in the scintigraphic and test results according to different tumor types were in agreement with published data on the density of somatostatin receptors measured by in vitro studies or scintigraphy and by the therapeutic effects of octreotide.

Key Words: octreotide • 123I-Tyr-3 • carcinoid tumor • endocrine tumor






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 1994 by the Society of Nuclear Medicine.